Hans Lennart Rudolf Wigzell sold $1.8M of SRPT
director at Sarepta Therapeutics, Inc.. 15,000 shares at an average of $123.25, traded Mar 8, 2024, filed Mar 11, 2024.
Score components
- +15RoleDirector
- +25Trade size$1.8M at market
- +10Share of holdings soldSold 40% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-029536, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 8, 2024 | MOption exercise Common Stock | +15,000 | $13.90 | $209k | 37,840 | Mar 11, 2024 |
| Mar 8, 2024 | SOpen-market sale Common Stock | -3,155 | $123.85 | $391k | 34,685 | Mar 11, 2024 |
| Mar 8, 2024 | SOpen-market sale Common Stock | -11,745 | $123.10 | $1.4M | 22,940 | Mar 11, 2024 |
| Mar 8, 2024 | SOpen-market sale Common Stock | -100 | $122.39 | $12k | 22,840 | Mar 11, 2024 |
| Mar 8, 2024 | MOption exercise Stock Option (right to buy)derivative | -15,000 | $0.00 | $0 | 0 | Mar 11, 2024 |
Related signals
Other insiders at Sarepta Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | SRPTsell Sarepta Therapeutics, Inc. | Stephen Mayo director | $123k 7,239 shares | -80% | |
| 34Weak | SRPTsell Sarepta Therapeutics, Inc. | Ian Michael Estepan Chief Operating Officer | $294k 13,187 shares | -6% | |
| 43Moderate | Sarepta Therapeutics, Inc. | Hans Lennart Rudolf Wigzell director | $1.3M 10,500 shares | -31% | |
| 40Moderate | Sarepta Therapeutics, Inc. | Kathryn Jean Boor director | $205k 1,636 shares | -22% | |
| 23Weak | Sarepta Therapeutics, Inc. | Bilal Arif Chief Tech Ops Officer | $1.9M 11,757 shares | -40% | |
| 33Weak | Sarepta Therapeutics, Inc. | Ryan Edward Brown EVP, General Counsel | $6.3M 38,957 shares | -69% | |
| 40Moderate | Sarepta Therapeutics, Inc. | Kathryn Jean Boor director | $94k 761 shares | -9% | |
| 56Moderate | Sarepta Therapeutics, Inc. | Stephen Mayo director | $385k 3,135 shares | -32% | |
| 43Moderate | Sarepta Therapeutics, Inc. | Bilal Arif Chief Tech Ops Officer | $258k 2,000 shares | -7% | |
| 43Moderate | Sarepta Therapeutics, Inc. | Ryan Edward Brown EVP, General Counsel | $251k 2,000 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.